Subscribe to Newsletter

Refine results:

Refine results


Subspecialties Oncology

The pathologist's impact on clinical practice & patients' lives

, 11:00am ET | Sponsored by Exact Sciences

We are delighted to welcome you to this webinar, sponsored by Exact Sciences*, about the changing role of pathologists in the area of precision oncology.

Diagnostics Liquid biopsy

Implementing liquid biopsy testing in a routine lab

, 11:00AM ET | Sponsored by Labcorp

The goal of this webinar is to share the learnings around the ease of onboarding a liquid biopsy solution in a laboratory setting

Diagnostics Oncology

Multicenter study of the Oncomine Comprehensive Assay Plus for local comprehensive molecular profiling

, 5pm CET | Sponsored by Thermo Fisher Scientific

In this webinar, Dr. Jantus-Lewintre shares her lab's experience evaluating the Oncomine Comprehensive Assay Plus

Subspecialties Oncology

Elevating the Standard of Pathogenic Variant Detection in Myeloid Cancers

| Sponsored by Bionano

In this Bionano in Motion webinar, we explore the utility and validity of an innovative strategy, proposed by Dr. Kolhe’s lab, from Augusta University, that combines optical genome mapping (OGM) with a comprehensive 523-gene next-generation sequencing (NGS) panel. This unique approach was meticulously evaluated against more traditional methods including karyotyping, fluorescent in situ hybridization (FISH), and a 54-gene NGS panel.

Subspecialties Microbiology and immunology

Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response

| Sponsored by Vizgen

We are thrilled to invite you to our upcoming online webinar, where we will delve into groundbreaking research on the spatial organization of immune cells in human tumors and its impact on immunotherapy outcomes.

Diagnostics Liquid biopsy

Clinical implications of comprehensive genomic profiling on liquid biopsy for lung cancer patients

| Sponsored by Illumina

In this webinar, Dr Federico Cappuzzo will speak about clinical implications of liquid biopsy-based CGP for lung cancer patients, discussing current clinical evidence and sharing his vision on future applications.

Diagnostics COVID-19

Using Single-Cell Sequencing to Investigate Murine COVID-19 Mortality

| Sponsored by Illumina, Parse Bio

Join Illumina and Parse Biosciences for a webinar where our invited speaker will present results of his recent single-cell study.

Subspecialties Oncology

Adjuvant COX Inhibition Augments Cytolytic T Cell Infiltration in Irradiated Triple Negative Breast Tumors

| Sponsored by Ultivue

Immune therapy has emerged as the new frontier of cancer treatment.

Subspecialties Oncology

Identifying HER2-low expression – A pathologist led slide review

| Sponsored by Roche

Roche Tissue Diagnostics invites you to learn more about the importance of identifying each level of HER2 expression.

Inside the Lab Digital and computational pathology

Embracing Pathology’s Digital Transformation

| Sponsored by Leica Biosystems

Pathologists from the US, Japan and Europe participate in a LIVE panel, to share their expert voices.

Diagnostics Biochemistry and molecular biology

Digital Spatial Profiling for Biomarker Discovery – 18,000-plex

| Sponsored by NanoString

This webinar will discuss these approaches to spatial analysis and include an example of both protein and mRNA assessment of tissue using DSP as a biomarker discovery tool.

Outside the Lab Regulation and standards

Illumina - Your partner in the transition to IVDR

| Sponsored by Illumina

Join Illumina for an educational webinar on the new EU IVD Regulation.

Diagnostics Genetics and epigenetics

Hunt for pathogenic variants in Type 2 diabetes through NGS

| Sponsored by Revvity

In this webinar, Dr. Amelie Bonafond will present the current sequencing (via whole-exome sequencing) of all the patients with common T2D visiting the department of Diabetology of Liège Hospital (n > 4000 participants).

Subspecialties Oncology

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

| Sponsored by Ultivue

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized.

Subspecialties Oncology

Two Perspectives: Patient and Hematopathologist Discussion on Importance of CML Monitoring

| Sponsored by Cepheid

Patients diagnosed with CML 20 years ago could live for around five years.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine